Table 6. Changes in CRP, NLR, and PASI between baseline and week 12 among therapy subgroups.
| Changes in PASI | Changes in CRP | Changes in NLR | |
|---|---|---|---|
| Therapy group | |||
| Adalimumab (n=19) | |||
| Min-max (med) | 0-31.9 (18.9) | −2.3-13.2 (0.4) | −0.2-5 (0.5) |
| Mean±SD | 18.46±9.21 | 2.47±4.14 | 1.01±1.24 |
| Acitr etin (n=11) | |||
| Min-max (med) | 4.2-14 (10.4) | −1.5-6.2 (0.5) | −0.1-1.7 (0.8) |
| Mean±SD | 9.55±3.63 | 1.61±2.36 | 0.72±0.65 |
| NB-UVB (n=7) | |||
| Min-max (med) | 6.4-18.2 (10.5) | −0.7-13.5 (1.3) | −0.9-2.1 (0.7) |
| Mean±SD | 12.13±4.61 | 3.03±4.99 | 0.51±1.05 |
| Etanercept (n=12) | |||
| Min-max (med) | 1.3-32.3 (13.5) | 1.3-8.5 (0.6) | −0.3-1.4 (0.6) |
| Mean±SD | 13.16±10.37 | 1.54±2.59 | 0.58±0.64 |
| MTX (n=30) | |||
| Min-max (med) | 1.6-27.4 (9.1) | −2.3-10 (0.7) | −1.4-2.6 (0.1) |
| Mean±SD | 9.49±6.27 | 1.49±2.58 | 0.11±0.73 |
| Cyclosporine (n=12) | |||
| Min-max (med) | −0.8-37.7 (13.4) | −0.3-9.2 (1.2) | −0.8-2.6 (0.5) |
| Mean±SD | 13.63±10.65 | 2.78±3.35 | 0.91±1.23 |
| Ustekinumab (n=9) | |||
| Min-max (med) | 5-24.5 (10.2) | −0.8-6.3 (0.5) | −1.1-0.8 (0.3) |
| Mean±SD | 12.11±6.4 | 1.65±2.36 | 0.12±0.62 |
| Test value (χ2) | 13.525 | 0.967 | 14.839 |
| p-value | 0.035*,† | 0.987* | 0.022*,† |
| ADA-acitretin | |||
| p-value | 0.042†,‡ | ||
| ADA-MTX | |||
| p-value | 0.007‡,§ | 0.007§,‡ |
CRP: C-reactive protein, NLR: Neutrophil-lymphocyte ratio, ADA: adalimumab, MTX: methotrexate, Min: minimum, max: maximum, med: median, PASI: Psoriasis Area and Severity Index. *Kruskal–Wallis test, ‡Mann–Whitney U-test, †p<0.05, §p<0.01.